Neurofibromatosis type 1 laboratory findings

Jump to navigation Jump to search

Neurofibromatosis type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibromatosis type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibromatosis type 1 laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibromatosis type 1 laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibromatosis type 1 laboratory findings

CDC on Neurofibromatosis type 1 laboratory findings

Neurofibromatosis type 1 laboratory findings in the news

Blogs on Neurofibromatosis type 1 laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Neurofibromatosis type 1 laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.

Overview

Metabolic and chemical laboratory studies usually appear normal in individuals with neurofibromatosis type 1. NF1 gene mutation can be diagnosed using linkage analysis and gene sequencing.

Laboratory Findings

References

  1. 1.0 1.1 Messiaen L, Riccardi V, Peltonen J, Maertens O, Callens T, Karvonen SL, Leisti EL, Koivunen J, Vandenbroucke I, Stephens K, Pöyhönen M (February 2003). "Independent NF1 mutations in two large families with spinal neurofibromatosis". J. Med. Genet. 40 (2): 122–6. doi:10.1136/jmg.40.2.122. PMC 1735368. PMID 12566521.
  2. 2.0 2.1 Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G (August 2007). "Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors". J Genet Couns. 16 (4): 387–407. doi:10.1007/s10897-007-9101-8. PMC 6338721. PMID 17636453.
  3. 3.0 3.1 3.2 "Neurofibromatosis Type 1 Workup: Laboratory Studies, Imaging Studies, Other Tests".
  4. 4.0 4.1 4.2 Allanson JE, Upadhyaya M, Watson GH, Partington M, MacKenzie A, Lahey D, MacLeod H, Sarfarazi M, Broadhead W, Harper PS (November 1991). "Watson syndrome: is it a subtype of type 1 neurofibromatosis?". J. Med. Genet. 28 (11): 752–6. doi:10.1136/jmg.28.11.752. PMC 1017110. PMID 1770531.
  5. 5.0 5.1 Alwan S, Tredwell SJ, Friedman JM (May 2005). "Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)?". Clin. Genet. 67 (5): 378–90. doi:10.1111/j.1399-0004.2005.00410.x. PMID 15811002.
  6. 6.0 6.1 6.2 6.3 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A, Friedman JM. PMID 20301288. Vancouver style error: initials (help); Missing or empty |title= (help)
  7. "www.aeped.es" (PDF).

Template:WH Template:WS